Literature DB >> 6721998

Interindividual variations in metoprolol metabolism--some clinical and other observations.

C G Regårdh, G Johnsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6721998      PMCID： PMC1463401          DOI： 10.1111/j.1365-2125.1984.tb02381.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris.

Authors:  H Halkin; I Vered; A Saginer; B Rabinowitz
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

2.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

3.  Lack of evidence for polymorphism in metoprolol metabolism.

Authors:  D B Jack; M Wilkins; C P Quarterman
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

4.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

5.  Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.

Authors:  U Thadani; C Davidson; W Singleton; S H Taylor
Journal:  N Engl J Med       Date:  1979-04-05       Impact factor: 91.245

6.  Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents.

Authors:  O Lyngstam; L Rydén
Journal:  Acta Med Scand       Date:  1981
  6 in total
  5 in total

1.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 3.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 4.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

Review 5.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.